Roche, Exelixis Seek FDA Approval on Melanoma Combo

Dec 16, 2014

Exelixis and collaborator Genentech, a member of the Roche Group, have filed a New Drug Application (NDA) with the FDA for a combination melanoma treatment.

The combination features cobimetinib, a specific MEK inhibitor discovered by Exelixis, and Roche's Zelboraf, already on the market.

According to FierceBiotech, in a Phase III study disclosed over the summer, the combination treatment helped subjects live significantly longer without tumor growth than those treated with Zelboraf alone. Patients treated with the combination reported a median progression-free survival of 9.9 months compared to 6.2 months on Zelboraf, the companies reported.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments